Development of novel treatment strategies based on knowledge of cellular dysfunction in diabetes (BetaBat)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2011
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
  • Location: Europe


The European project BetaBat aims to develop new treatment strategies based on knowledge of cellular dysfunction in diabetes.


BetaBat will perform a detailed organelle diagnosis based on both focused and systems biology approaches, which will provide the scientific rationale for the design of specific interventions to boost the capacity of beta cells and brown adipocytes to regain homeostatic control. The project proposes that only by understanding the complex molecular mechanisms triggering cellular dysfunction in diabetes, and by integrating this knowledge at the systems level, will it be possible to develop interventional therapies that protect and restore beta cell and BAT function. The ultimate goal is to offer individual therapeutic choices based on both genetic information and organelle diagnosis.

Consortium History

The project was launched in October 2011.


BetaBat is a collaborative project funded by the European Commission under the Seventh Framework Programme.

Points of Contact

Prof. D├ęcio L. Eizirik (coordinator)
U.L.B. CP618
Route de Lennik 808
1070 Brussels (Anderlecht)
phone: ++32 (0)2 555 6242

Sponsors & Partners

DNA Vision SA

Lund University

Medizinische Hochschule Hannover

Sanford-Burnham Medical Research Institute

Sirion Biotech

Universitat de Barcelone

Universite de Lausanne

Universite Libre de Bruxelles

University of Cambridge

VTT Technical Research Centre of Finland

Last Updated: 04/14/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.